Celyad Oncology S.A.
CYADNASDAQHealthcare
$0.47
$-0.07(-12.96%)
Market Cap$14238462
P/E Ratio—
52W High$3.07
52W Low$0.15
Celyad Oncology S.A. (CYAD) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CYAD · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.19M | $0.10M | $0.00M | $0.00M | $0.01M |
| Cost of Revenue | $0.01M | $0.07M | $1.44M | $1.52M | $0.00M |
| Gross Profit | $0.17M | $0.03M | ($1.44M) | ($1.52M) | $0.01M |
| Gross Margin %(computed) | 93.55% | 32.35% | — | — | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $3.31M | $4.67M | $18.93M | $20.77M | $21.59M |
| G&A Expenses | $3.09M | $5.71M | $10.34M | $9.66M | $9.31M |
| Total Operating Expenses | $6.03M | $8.49M | $20.26M | $26.91M | $26.24M |
| Operating Income | ($5.86M) | ($8.46M) | ($40.86M) | ($26.39M) | ($16.99M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.03M | $0.03M | $0.01M | $0.03M | $0.22M |
| Interest Expense | $0.00M | $0.08M | $0.20M | $0.26M | $0.43M |
| Income Before Tax | ($5.82M) | ($8.64M) | ($40.87M) | ($26.50M) | ($17.20M) |
| Income Tax Expense | $0.00M | ($0.19M) | $0.07M | $0.01M | $0.00M |
| Net Income | ($5.82M) | ($8.45M) | ($40.94M) | ($26.51M) | ($17.50M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.14 | $-0.33 | $-1.81 | $-1.70 | $-1.26 |
| Wtd Avg Shares | 41.43M | 25.72M | 22.59M | 15.60M | 13.94M |
| EBITDA | ($5.69M) | ($7.76M) | ($39.70M) | ($25.41M) | ($14.94M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · EUR · M
Explore more Celyad Oncology S.A. data
About Celyad Oncology S.A. (CYAD) Income Statement
Celyad Oncology S.A. (CYAD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, CYAD reported revenue of $0.00B, gross profit of $0.00B (gross margin 93.55%), and net income of ($0.01B) — a net profit margin of -3131.18%.
Frequently asked questions
CYAD · 4 questionsCelyad Oncology S.A. (CYAD) reported revenue of $0.00B for 2024, up 82.4% year-over-year.
CYAD revenueCYAD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09